M&A / Deals Roche places a $1bn bet on C4T degrader-antibody conjugates PharmaphorumRoche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.M&A / DealsOncologyRead full story pharminent April 10, 2026 (Last updated: April 10, 2026) Pharmaphorum Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T. M&A / DealsOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Roche and C4 Therapeutics to advance degrader-antibody conjugates researchNext: GSK again pulls application for leucovorin, touted by FDA as potential autism treatment Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
